Quantcast

Boca Pharmacal receives FDA approval on Hydrocodone Bitartrate and Acetaminophen Oral Solution

July 22, 2011

Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Hydrocodone Bitartrate and Acetaminophen Oral Solution, 7.5mg / 325mg per 5mL, the generic version of Hycet® Oral Solution distributed by FSC Laboratories, Inc.

Coral Springs, Florida (PRWEB) July 21, 2011

Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Hydrocodone Bitartrate and Acetaminophen Oral Solution, 7.5mg / 325mg per 5mL, the generic version of Hycet® Oral Solution distributed by FSC Laboratories, Inc. Hydrocodone Bitartrate and Acetaminophen Oral Solution is used for treatment for the relief of moderate to moderately severe pain.

“This is our second approval this year,” said Robert Edwards, CEO of Boca Pharmacal. “And we expect more by year’s end. We have already filed a few ANDAs since January, an impressive feat for a small privately held pharmaceutical company.”

Boca Pharmacal, Inc.

Since its beginnings in 1998, Boca Pharmacal’s mission has been to offer niche items that were overlooked by some of the larger generic companies as affordable alternatives to brand-named products.

Using multiple facilities across the globe, Boca Pharmacal has a broad reach and a reliable vertical structure that allows them to develop products that include tablets and capsules, semi-solids, solutions, and suspensions. They continue to invest in research and development to make sure they’re providing their clients with a wide variety of offerings. The Boca Pharmacal product line is marketed to chains, wholesalers, distributors, managed markets and government agencies. Boca Pharmacal is located at 3550 NW 126th Avenue, Coral Springs, Florida, 33065.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/7/prweb8661616.htm


Source: prweb



comments powered by Disqus